



## NIH AIDS Reagent Program

20301 Century Boulevard  
Building 6, Suite 200  
Germantown, MD 20874  
USA

Phone: 240 686 4740  
Fax: 301 515 4015  
aidsreagent.org

### DATA SHEET

<b>Reagent:</b>	U87 CD4+CCR1+ Cells
<b>Catalog Number:</b>	4032
<b>Lot Number:</b>	020012
<b>Release Category:</b>	C
<b>Provided:</b>	2 x 10 <sup>5</sup> cells/vial. Viability is 95%.
<b>Cell Type:</b>	Human astrocytoma (glioblastoma) cells
<b>Propagation Medium:</b>	DMEM, 85%; fetal bovine serum, 15%. Supplement with 1 µg/ml puromycin, 300 µg/ml G418, glutamine, and pen/strep.
<b>Freeze Medium:</b>	Fetal bovine serum, 90%; DMSO, 10%.
<b>Growth Characteristics:</b>	Cells divide slowly; however, they should not be allowed to become over-confluent. In general, pass cells at 80% confluency and split no more than 1:10. Sensitive to acidic medium.
<b>Sterility:</b>	Negative for mycoplasma, bacteria and fungi.
<b>Description:</b>	U87MG cells that express CD4 and CCR1.
<b>Special Characteristics:</b>	U87MG cells (cat# 2188) were stably transduced with the MV7neo-T4 retroviral vector and selected for G418 resistance to produce U87 CD4+ Cells (cat# 4031). Cells were subsequently transduced with pBABE-puro-CCR1 and selected for puromycin resistance. Human CD4 and CCR1 expression are each directed by the MV7 vector and BABE vector MLV LTR elements, respectively. U87 cells endogenously express the virus coreceptors GPR1 and Bonzo/STRL33, which can be used by certain SIV and HIV-2 isolates for cell entry. These cells may be contaminated with amphotropic MLV.  Alternate names: U87.CD4.CCR1

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

**Recommended Storage:** Liquid Nitrogen

**Contributor:** Dr. HongKui Deng and Dr. Dan Littman.

**References:** Björndal A, Deng H, Jansson M, Fiore JR, Colognesi C, Karlsson A, Albert J, Scarlatti G, Littman DR, Fenyo EM. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. *J Virol* **71**:7478–7487, 1997.

**NOTE:** Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: U87 CD4+CCR1+ Cells from Dr. HongKui Deng and Dr. Dan R. Littman." Also include the reference cited above in any publications.

**Patent pending. Scientists at for-profit institutions or who intend commercial use of this reagent must contact the New York University Office of Industrial Liaison at the following email address: [abram.goldfinger@nyumc.org](mailto:abram.goldfinger@nyumc.org).**

**Last Updated** June 22, 2017

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.